Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib — StellaPhase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(36 sites)
France
CHRU Jean Minjoz, Besançon Centre Régional de Lutte contre le cancer - Institut Bergonié, Bordeaux CHU de BREST - Hôpital Cavale Blanche, Brest Centre François Baclesse, Caen Last updated December 2025